vs
Side-by-side financial comparison of Spero Therapeutics, Inc. (SPRO) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
Valens Semiconductor Ltd. is the larger business by last-quarter revenue ($17.3M vs $12.6M, roughly 1.4× Spero Therapeutics, Inc.). Spero Therapeutics, Inc. runs the higher net margin — 250.7% vs -42.2%, a 292.9% gap on every dollar of revenue. On growth, Spero Therapeutics, Inc. posted the faster year-over-year revenue change (24080.8% vs 8.1%).
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
SPRO vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.6M | $17.3M |
| Net Profit | $31.5M | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | — | -46.4% |
| Net Margin | 250.7% | -42.2% |
| Revenue YoY | 24080.8% | 8.1% |
| Net Profit YoY | 250.9% | 29.3% |
| EPS (diluted) | $0.56 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.6M | — | ||
| Q3 25 | $0 | $17.3M | ||
| Q2 25 | $0 | $17.1M | ||
| Q1 25 | $12.0K | $16.8M | ||
| Q4 24 | $52.0K | — | ||
| Q3 24 | $65.0K | $16.0M | ||
| Q2 24 | $114.0K | $13.6M | ||
| Q1 24 | $140.0K | — |
| Q4 25 | $31.5M | — | ||
| Q3 25 | $-7.4M | $-7.3M | ||
| Q2 25 | $-1.7M | $-7.2M | ||
| Q1 25 | $-13.9M | $-8.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-17.1M | $-10.4M | ||
| Q2 24 | $-17.9M | $-8.9M | ||
| Q1 24 | $-12.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -46.4% | ||
| Q2 25 | — | -43.3% | ||
| Q1 25 | -122758.3% | -56.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | -28604.6% | -76.3% | ||
| Q2 24 | -16720.2% | -69.2% | ||
| Q1 24 | -9987.1% | — |
| Q4 25 | 250.7% | — | ||
| Q3 25 | — | -42.2% | ||
| Q2 25 | — | -42.1% | ||
| Q1 25 | -115550.0% | -49.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | -26380.0% | -64.6% | ||
| Q2 24 | -15668.4% | -65.2% | ||
| Q1 24 | -9049.3% | — |
| Q4 25 | $0.56 | — | ||
| Q3 25 | $-0.13 | $-0.07 | ||
| Q2 25 | $-0.03 | $-0.07 | ||
| Q1 25 | $-0.25 | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.32 | $-0.10 | ||
| Q2 24 | $-0.33 | $-0.08 | ||
| Q1 24 | $-0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.3M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $59.0M | $108.8M |
| Total Assets | $68.9M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.3M | — | ||
| Q3 25 | $48.6M | $93.5M | ||
| Q2 25 | $31.2M | $102.7M | ||
| Q1 25 | $48.9M | $112.5M | ||
| Q4 24 | $52.9M | — | ||
| Q3 24 | $76.3M | $133.1M | ||
| Q2 24 | $63.5M | $105.9M | ||
| Q1 24 | $82.3M | — |
| Q4 25 | $59.0M | — | ||
| Q3 25 | $26.5M | $108.8M | ||
| Q2 25 | $32.8M | $116.5M | ||
| Q1 25 | $33.8M | $128.6M | ||
| Q4 24 | $46.1M | — | ||
| Q3 24 | $65.5M | $147.0M | ||
| Q2 24 | $80.5M | $153.5M | ||
| Q1 24 | $96.2M | — |
| Q4 25 | $68.9M | — | ||
| Q3 25 | $54.2M | $136.7M | ||
| Q2 25 | $62.1M | $144.8M | ||
| Q1 25 | $77.7M | $154.6M | ||
| Q4 24 | $110.5M | — | ||
| Q3 24 | $135.2M | $171.9M | ||
| Q2 24 | $149.9M | $175.8M | ||
| Q1 24 | $167.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.4M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-4.9M |
| FCF MarginFCF / Revenue | — | -28.5% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | -0.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-8.4M | — | ||
| Q3 25 | $17.4M | $-4.7M | ||
| Q2 25 | $-17.7M | $-211.0K | ||
| Q1 25 | $-4.0M | $-7.6M | ||
| Q4 24 | $-23.4M | — | ||
| Q3 24 | $12.8M | $3.0M | ||
| Q2 24 | $-18.7M | $-225.0K | ||
| Q1 24 | $5.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.9M | ||
| Q2 25 | — | $-330.0K | ||
| Q1 25 | — | $-8.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | — | $-460.0K | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | — | -1.9% | ||
| Q1 25 | — | -47.3% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 14.0% | ||
| Q2 24 | — | -3.4% | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 0.7% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.5% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | — |
| Q4 25 | -0.26× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
